Bernstein Initiates Coverage of Summit Therapeutics (SMMT) with Underperform Recommendation
23/5 01:26
Fintel reports that on May 22, 2026, Bernstein initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Underperform recommendation. Analyst Price Forecast Suggests 72.66% Upside...